BioSpace News Archive

OrganaBio products and services can now be accessed via the Science Exchange and Scientist.com platforms.

TELA Bio, Inc. (NASDAQ: TELA) today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase.

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced it will host an in-person KOL event on Wednesday, September 20, 2023 at 3:00pm ET at The New York EDITION Hotel.

Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets.

Elutia Inc. announced the divestiture of the Company’s Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd. Elutia will receive cash proceeds of up to $35 million, comprised of an upfront payment at closing of $15 million plus potential earnout payments of up to $20 million over a five-year period.

ImmunoGen, Inc. announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen’s Senior Vice President and Chief Financial Officer, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units covering 51,625 shares of its common stock under the Inducement Plan to Ms. White.

Primrose Bio, Inc. has been established as a result of the combination between Primordial Genetics, Inc. and Pelican Technology Holdings, Inc. As part of the transaction, Ligand Pharmaceuticals has contributed $15 million in funding.

Codexis, Inc., a leading enzyme engineering company, announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award.

Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023.

60 Degrees Pharmaceuticals, Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious diseases, today announced that 60P Australia Pty Ltd, a majority-owned subsidiary of 60P, has withdrawn its investigational new drug (IND) application for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19, and intends to submit a new IND in the fourth quarter.